Clinical Trial

A new chemo-free combo from Genmab and AbbVie shows a 60% reduction in disease progression for a tough-to-treat blood cancer, setting a new standard.

With FDA approval for its pivotal TRIUMPH trial, Laplace Interventional is challenging giants in the lucrative tricuspid valve market. A strategic play.

Onkos Surgical hit 500 cases with its NanoCept antibacterial coating. Is this nano-scale tech the key to winning the war on devastating surgical infections?

A wave of precision drugs for Nephrotic Syndrome is set to transform patient lives and a quiet $400M market, revealing a major shift in pharma strategy.

CraniUS Therapeutics secures up to $4M in NIH funding for its NeuroPASS device, a refillable implant aiming to revolutionize glioblastoma and CNS treatment.

A new patent in South Korea for a novel breast cancer vaccine offers a potential paradigm shift from treatment to prevention, but the road from patent to patient is long.

With its fibromyalgia drug now on the market, Tonix is expanding its use to MDD, targeting disturbed sleep in a novel approach for millions of patients.

With a new FDA Fast Track designation, Satellos Bioscience aims to accelerate its unique muscle-regenerating drug for Duchenne, a strategy that could sidestep genetic limitations.

Beyond the hype, Eisai's latest data on at-home Alzheimer's treatment and a new anti-tau drug signals a seismic shift in patient care and market strategy.

WideTrial's innovative program hit a major milestone, providing 200 ALS patients with an investigational drug and creating a new model for compassionate use.

A German biotech just completed a key trial for a cell therapy that could teach the body to accept a new kidney, freeing patients from a lifetime of harsh drugs.

Positive interim data for a world-first CBD insomnia trial de-risks development, promising a safer alternative to current drugs and igniting global interest.

Early results for AB Science's AB8939 show a 67% response rate in high-risk AML patients, offering a potential breakthrough where other treatments fail.

An independent safety board just gave Medera's novel gene therapy for a stubborn form of heart failure a major endorsement, de-risking its path to the FDA.

NeuroSense's PrimeC shows intriguing biomarker activity against Alzheimer's, targeting multiple disease pathways. Is this the shift away from single-target drugs?

Servier's new trial for a fatal pediatric epilepsy is more than a medical milestone; it's a strategic bet on high-risk, high-reward rare disease markets.

Promising 3-year survival data for a novel immunotherapy combo offers new hope for patients with MSS colorectal cancer, a notoriously difficult disease.

A landmark publication in The Lancet unveils AC01, a novel oral drug that safely improves heart function, offering a beacon of hope for millions with heart failure.

By fast-tracking its novel oral drug for atopic dermatitis, Kymera isn't just advancing a treatment—it's validating a new class of medicine.